Servier launches VC unit focused on European biotech startupsnews2026-01-08T19:24:49+00:00January 8th, 2026|Endpoints News|
FDA staff cuts mostly didn’t impact new drug review timelines, analysis findsnews2026-01-08T19:20:55+00:00January 8th, 2026|Endpoints News|
New Lilly data suggest Zepbound boosted effect of autoimmune drugnews2026-01-08T19:00:03+00:00January 8th, 2026|Endpoints News|
Secretive Rampart Bioscience closes after pursuing non-viral gene therapynews2026-01-08T17:59:21+00:00January 8th, 2026|Endpoints News|
FDA rejects Vanda’s jet lag drug following yearslong dispute news2026-01-08T16:19:50+00:00January 8th, 2026|Endpoints News|
MoonLake revives FDA push; Biotech trio to debut in Hong Kongnews2026-01-08T16:15:06+00:00January 8th, 2026|Endpoints News|
FDA drug and biologic approvals list 2025: Sign-offs dip during agency upheavalnews2026-01-08T16:00:45+00:00January 8th, 2026|Endpoints News|
HHS loses bid to suspend court block on 340B rebate pilotnews2026-01-08T15:57:49+00:00January 8th, 2026|Endpoints News|
Deregulating the rapidly evolving digital health industrynews2026-01-08T15:34:52+00:00January 8th, 2026|Endpoints News|
Charles River CEO Jim Foster to retire; Samsung Bio buys a GSK factorynews2026-01-08T15:20:54+00:00January 8th, 2026|Endpoints News|
